Juno Therapeutics CEO Bishop on Immunotherapy

The video discusses the development and challenges of CART and TCR cell therapies for cancer treatment. It highlights the importance of market timing, the competition between companies like Juno and Kite, and the difficulties in treating acute lymphoblastic leukemia. Safety concerns and the potential impact of healthcare policies on these therapies are also addressed. The video concludes with a discussion on the pricing and value of these treatments in the healthcare system.

What is the primary focus of CART and TCR cell therapies?

• To eliminate all side effects

• To improve clinical results

• To be the first to market

• To reduce treatment costs

What was the main issue faced by Juno in their CART trials?

• Lack of funding

• Patient deaths

• Regulatory hurdles

• Ineffective technology

Why is acute lymphoblastic leukemia challenging to treat with immunotherapy?

• CAR T cells grow too slowly

• The tumor is resistant to treatment

• CAR T cells grow too quickly

• The disease is rare

What is a concern regarding the rapid development of powerful technologies in the industry?

• Insufficient focus on safety

• High costs

• Limited market potential

• Lack of innovation

What is the estimated value generation per patient if CAR T cell therapy cures 50% of pediatric AALL cases?

• $1,000,000

• $750,000

• $500,000

• $1,250,000

What is the potential impact of dismantling Obamacare on companies developing CAR T therapies?

• More hospital trials

• Uncertain reimbursement environment

• Decreased healthcare costs

• Increased innovation

What is the standard of care for leukemia that CAR T therapies aim to improve upon?

• Metallica cell transplant

• Immunotherapy

• Radiation therapy

• Chemotherapy